Data Type
Evidence Tier
Year
From
to
A comprehensive, evidence-based guide to myopia (nearsightedness), epidemiology, risk factors, and the latest control treatments backed by clinical research.
Myopia (nearsightedness) is the fastest-growing pediatric eye condition in the world. By 2050, nearly half the global population is projected to be myopic, and the rate among American children has doubled in a generation. Behind that statistic is a flood of new research: hundreds of studies, dozens of treatments, and constantly evolving clinical guidance.
This navigator is our attempt to make that research accessible. Each of the 170 entries above has been read, scored, and summarized in plain English. Studies are graded on a 10-point scale across three tiers (Gold Standard, Strong, Moderate) based on study design, journal quality, sample size, and consistency with International Myopia Institute (IMI) 2025 and Cochrane Library standards.
Use the sidebar to browse by topic (atropine, orthokeratology, MiSight, spectacles, environmental factors). Use the search bar to find a specific study, author, or treatment. The built-in risk calculator helps you understand your child's risk profile based on age, prescription, family history, outdoor time, and screen use.
Myopia is a refractive error where distant objects appear blurry while close objects stay clear. It happens because the eyeball grows too long, causing light to focus in front of the retina instead of on it. In children, myopia typically begins between ages 6 and 14 and tends to progress (get worse) until the late teens or early twenties.
Yes. Multiple evidence-backed treatments have been shown in clinical trials to slow myopia progression by 30% to 70%. The main categories are low-dose atropine eye drops, orthokeratology (overnight reshaping contact lenses), specialty soft contact lenses like MiSight, and specialty spectacle lenses like Stellest or MiYOSMART. Best results often come from combining approaches under specialist supervision.
The general consensus among myopia specialists, including the International Myopia Institute, is that treatment should start as soon as myopia is diagnosed, especially in children under 10. Earlier intervention saves more years of progression and reduces the lifetime risk of complications like retinal detachment and myopic maculopathy.
The major treatments (atropine eye drops, orthokeratology, MiSight contact lenses, DIMS spectacles) have been studied in long-term clinical trials and are considered safe when prescribed and monitored by an eye care professional. Side effects are typically mild, such as light sensitivity with atropine or a brief adjustment period with contact lenses. Untreated high myopia carries far greater long-term risks than the treatments do.
Research suggests at least 2 hours per day of outdoor light exposure reduces the chance of developing myopia by 25% to 50%. The protective effect comes from bright natural light, not from any specific outdoor activity. This is the single most cost-effective myopia prevention strategy and works best before myopia begins.
Every child should have a comprehensive eye exam by age one, again before kindergarten, and then annually through their school years, even if they show no symptoms. Children with myopic parents or other risk factors should be examined more frequently. Watch for squinting, sitting close to screens, holding books unusually close, or complaints of headaches and tired eyes.
Insight Vision Optometry โ Myopia Research Navigator โข Last Updated:
This research navigator is an educational tool. It does not constitute medical advice. Always consult qualified healthcare providers for diagnosis and treatment decisions.
The Cochrane myopia interventions review cited herein (Lawrenson et al. 2025) is a systematic review that updates periodically. Check the Cochrane Library for the latest version.